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Restoring immune tolerance in
neuromyelitis optica
Part II
ABSTRACT
Neuromyelitis optica spectrum disorder (NMO/SD) and its clinical variants have at their core the
loss of immune tolerance to aquaporin-4 and perhaps other autoantigens. The characteristic phe-
notype is disruption of astrocyte function and demyelination of spinal cord, optic nerves, and par-
ticular brain regions. In this second of a 2-part article, we present further perspectives regarding
the pathogenesis of NMO/SD and how this disease might be amenable to emerging technologies
aimed at restoring immune tolerance to disease-implicated self-antigens. NMO/SD appears to be
particularly well-suited for these strategies since aquaporin-4 has already been identified as the
dominant autoantigen. The recent technical advances in reintroducing immune tolerance in exper-
imental models of disease as well as in humans should encourage quantum leaps in this area that
may prove productive for novel therapy. In this part of the article series, the potential for regula-
tory T and B cells is brought into focus, as are new approaches to oral tolerization. Finally, a road-
map is provided to help identify potential issues in clinical development and guide applications in
tolerization therapy to solving NMO/SD through the use of emerging technologies. Each of these
perspectives is intended to shine new light on potential cures for NMO/SD and other autoimmune
diseases, while sparing normal host defense mechanisms. Neurol Neuroimmunol Neuroinflamm
2016;3:e277; doi: 10.1212/NXI.0000000000000277
GLOSSARY
AChR 5 acetylcholine receptor; AQP4 5 aquaporin-4; BcR 5 B cell receptor; Breg 5 regulatory B cell; EAE 5 experimental
autoimmune encephalomyelitis; GVHD 5 graft-vs-host disease; IBD 5 inflammatory bowel disease; IFN 5 interferon; IgG 5
immunoglobulin G; IL 5 interleukin; MS 5 multiple sclerosis; NMO 5 neuromyelitis optica; SD 5 spectrum disease; T1D 5
type 1 diabetes; TGFb 5 transforming growth factor b; Treg 5 regulatory T cell.
Neuromyelitis optica spectrum disorder (NMO/SD) remains a vexing neuroinflammatory and
demyelinating disease that most frequently involves the spinal cord and optic nerve(s).1 The
pathogenesis of NMO/SD stems from reactivity to aquaporin-4 (AQP4).2 Complement-fixing
antibodies directed against AQP4 can be detected in serum and/or CSF in a majority of
individuals diagnosed with NMO/SD. While existing agents may appear clinically beneficial,
none has proven effectiveness or received regulatory approval for NMO/SD.3 Nonspecific
immunosuppressant therapies often have adverse effects that may be amplified over chronic
exposure. These concerns compelled the Guthy-Jackson Charitable Foundation to facilitate
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development of strategies for retolerization to
AQP4 as potentially curative solutions for
NMO/SD. Several experts in NMO/SD and
immunology have contributed to this second
of a 2-part series. Here, the state of the art in
restoring immune tolerance is examined, and
a roadmap is presented for developing antigen-
specific approaches to NMO/SD. This discus-
sion addresses current understanding of B and
T cell immunobiology, distinct strategies for
tolerization and developmental milestones for
clinical application. The increasing awareness
and understanding of NMO/SD, and the dis-
ruption of immune function that it represents,
should provide opportunities for benefiting
patients with the disease.
POTENTIAL STRATEGIES FORRESTORING IMMUNE
TOLERANCE IN NMO/SD Enhancing regulatory T
cell function. Thymus-derived CD41CD251Foxp31
regulatory T cells (Tregs) have several roles in main-
taining immune self-tolerance.4,5 These cells undergo
thymic selection, then migrate to the periphery where
they perform their regulatory functions. Most Tregs
constitutively express CD25, the interleukin (IL)-2
receptor a-chain,6,7 and Foxp3,8 a transcription factor
involved in Treg function.9–11
Foxp3 deficiencies in Treg development and func-
tion cause abnormal immune tolerance in humans
and animal models.12–16 In scurfy mice, Foxp3 defi-
ciency results in Treg depletion, dysfunction, defec-
tive maturation, and lethal lymphoproliferative
disease.12–14 Affected patients develop polyendocrin-
opathy and enteropathy through X-linked inheritance,15
via defective Treg suppression of autoreactivity.16 It re-
mains unclear whether similar Treg abnormalities are
primarily involved in NMO/SD. Harnessing Tregs as
potential therapy might attenuate the overly aggressive
effector responses involved in its pathogenesis.
Tregs modulate activation and function of T cells,
B cells, natural killer cells, dendritic cells, macro-
phages, and mast cells (reviewed in reference 17).
For example, they can inhibit CD41 and CD81 T
cell proliferation, cytokine production, cytolysis, and
other effector cell functions. They can also prevent B
cells from generating autoreactive antibodies.18,19
Tregs elaborate soluble factors (e.g., IL-10, trans-
forming growth factor b [TGFb]), surface molecules
(CTLA-4 [cytotoxic T-lymphocyte–associated pro-
tein 4]), and generate indoleamine 2,3-dioxygenase,
which have been implicated in immune regulation.20
They kill target autoreactive cells through perforin-
and granzyme-mediated mechanisms, and inhibit T
cell–dendritic cell interactions, rendering T cell acti-
vation incomplete thus promoting anergy. Tregs have
been shown to have therapeutic benefit against both
autoreactive humoral and T cell responses in animal
models of type 1 diabetes (T1D), experimental auto-
immune encephalomyelitis (EAE), graft-vs-host dis-
ease (GVHD),21–23 and in human clinical trials for
GVHD and T1D (table).24,25 Antigen-specific Tregs
may be more effective in modulating autoimmune
responses than their polyclonal counterparts.21,26–28
The generation of therapeutic Tregs for NMO/SD
may be achieved using several strategies. While adminis-
tration of autologous polyclonal Tregs expanded in vitro
represents a logical first step for most indications, use of
AQP4-restricted Tregs might prove particularly effective
in NMO/SD. Creating genetically engineered T cells
with chimeric antigen receptors is one feasible approach
(see part I; reviewed in references 29 and 30). Because
chimeric antigen receptors comprise a single chain vari-
able fragment from a known antibody, this basic strategy
circumvents inadvertent or off-target major histocompat-
ibility complex restriction. For example, anti-AQP4
monoclonal antibody could be cloned into a lentiviral
vector such as single chain variable fragment, along with
an appropriate signaling domain, and transduced into
Tregs. Resulting cells should have tight AQP4 specificity
and retain antigen-directed immunosuppressive activity.5
Proof of concept for this strategy has been demonstrated
in a mouse model of colitis.31 Similarly, antigen-specific
human Tregs engineered through transduction of T cell
receptor into Foxp31 Tregs efficiently inhibited factor
VIII–specific T effector cells in hemophilia.29 Alterna-
tively, Ag-specific Tregs could be expanded ex vivo30,32
by exposure to recombinant AQP4 protein in the pres-
ence of IL-2, TGFb, and/or rapamycin. Thereafter,
AQP4-responsive Tregs could be isolated, expanded,
and administered to patients. It should be noted that,
while AQP4 is the prototypic autoantigen in NMO/SD,
others are emerging as candidate participants in this dis-
ease, such as myelin oligodendrocyte glycoprotein. If
validated, such antigens could be targeted using the strat-
egies outlined herein.
Enhancing regulatory B cell function. Abnormal B cell
functions may enhance autoimmune mechanisms,
including those associated with NMO/SD. These
cells can polarize naive CD41 T cells to Th1,
Th2, or Th17 phenotypes, present antigens, pro-
duce cytokines, and effect costimulation.33–38
Proinflammatory B cells that activate myeloid cells
(in turn, activating proinflammatory T cells) have
been implicated in human CNS autoimmune dis-
ease.39 Counterbalancing the multiple roles of
proinflammatory B cells are regulatory B cells (Bregs40).
Bregs polarize toward a Th2 bias and modulate immune
reactivity by way of IL-10 and TGFb production, and
a M2 macrophage phenotype. However, pathogenic
anti-AQP4 antibody is secreted by activated B
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plasma cells. Checkpoint dysfunction in plasma
cell precursors offsets these anti-inflammatory effects
of Th2 polarization and yields AQP4 autoantibody. In
turn, this process triggers proinflammatory complement
deposition. Thus, targeting autoreactive B cells may be an
effective goal for Breg enhancement of immune tolerance
in NMO/SD.
No cell markers are known to reliably discriminate
between Breg and proinflammatory B cells. Bregs
have demonstrated efficacy in attenuating autoim-
mune reactivity in animal models. For example,
B10 cells (CD1d-CD5hi) suppress T cell responses
in contact hypersensitivity.41 Furthermore, transi-
tional B cells (CD191CD21hiCD23hiCD1dhi) amelio-
rate experimental arthritis, TIM-11 B cells prolong islet
allograft survival in diabetic mice, and CD1dhi B cells
abrogate inflammatory bowel disease (IBD).42–45 Bregs
commonly express high levels of IL-10 and cell surface–
displayed CD1d.46 More recently, B cells expressing
IL-35 in the absence of IL-10 were also found to have
potent anti-inflammatory effects in EAE.47
Breg activation typically requires signaling via the
B cell receptor (BcR) as well as CD40/CD154 costi-
mulation. In humans, signaling through CD40 or toll-
like receptors induces IL-10 expression in naive
(CD272) B cells in the absence of BcR engage-
ment.48–53 However, profusive IL-10 or IL-35 induction
downregulates Breg functions47,49 and exacerbates auto-
immune diseases such as IBD, EAE, arthritis, and sys-
temic lupus erythematosus in experimental mice.54–57
IL-10 deficiency is also associated with multiple sclerosis
(MS) severity.49 These apparent paradoxes may reflect
the multiplicity of B cell functions in different immune
paradigms.42,49,55,58 TGFb,59,e1 IL-4, and interferon
(IFN)-g may differentially influence Breg function,
including their expression of major histocompatibility
complex class II.e3 B cell depletion using anti-CD20 as
in MSe2–e5 depletes B cells exhibiting proinflammatory
functions but not autoantibody levels.e6–e9
Selective depletion of inflammatory B cells target-
ing AQP4, or enhancement of Bregs targeting AQP4-
reactive B or T cells, holds potential therapeutic prom-
ise in NMO/SD. A bispecific monoclonal antibody
directed against the AQP4-restricted BcR and an
apoptosis-promoting surface determinant illustrates
an example of this strategy. Alternatively, adoptive trans-
fer of Bregs targeting pathogenic immune cells might
also prove effective. This strategy has shown efficacy
in attenuating disease severity in models of IBD, MS,
arthritis, and systemic lupus erythematosus.49,55,e10,e11
Table Potential strategies for restoring immune tolerance in NMO/SD
Tolerization
strategy
Material
source
Biological
source Primary target
Animal
studies Example study outcomes
Human
studies Example study outcomes
Inverse DNA
vaccine
Heterologous Engineered APC, Tc, and Bc
subsets
Yese53 Induction of tumor suppression Yese54 Reduction in proinsulin
autoreactive CD81 T cells
Autoreactive Tc
vaccine
Autologous Natural Autoreactive Tc Yese55 Mortality reduced from 50% to
0% in SJL/J mice
Yese56 Induction of CD81 Tc attenuated
T1D severity
Dendritic cell
vaccine
Autologous Natural AQP4
presentation
Yese57,e58 Tolerogenic DC vaccine protective
in EAE model
Yese59 Mixed outcomes of Ag-specific
DC in T1D
Ag-coupled
presentation
Autologous Engineered AQP4
presentation
Yese60 Expansion of Ag-specific CD41
and CD81 Tc
Yese61 Treg reactivity to myelin Ag
peptide in patients with MS
Tc receptor
engineering
Autologous Engineered Autoreactive Tc Yese62,e63 Induction of Treg subset in mouse
EAE model
Yese64 Moderate efficacy in human
malignancies
Regulatory Tc
induction
Autologous Natural Proinflammatory
cells/pathways
Yes21–
23,29,e65
Treg induction in various
preclinical models
Yese66 Expansion of Treg subset
attenuates inflammation
Regulatory Bc
induction
Autologous Natural Proinflammatory
cells/pathways
Yes41–
45,49,55,
e10–e13,e67
Suppression of Tc autoreactivity;
binding immunoglobulin protein
induces Breg
No NA
Oral/mucosal
tolerization
Recombinant Either APC, Tc, and Bc
subsets
Yese14,e17,
e27–e31
CD41CD251Foxp31LAP1 Treg
induction in various preclinical
models
Yese15,
e16,e28,
e29
Lower TNF-a, higher IL-10
induction by Ag-specific Tc;
allergy desensitization
Adoptive
transfer
Autologous
or HLA-
matched
Conditioned
natural
APC, Tc, and Bc
subsets
Yese36,e37 Modest efficacy in murine arthritis
and lupus
Yese34,
e35
Efficacy in GVHD
Anti-idiotypic
networks
Heterologous Either Pathogenic Ab Yese41 Anti-idiotype induction in NOD
mouse model
Yese41,
e44,e45
IVIg efficacy in NMO/SD; anti-
idiotype induction in autoimmune
diseases
Passive
tolerization
Heterologous Either Pathogenic Ab Yese50 Passive aquaporumab efficacy in
EAE model
No NA
Abbreviations: Ab 5 antibody; Ag 5 antigen; APC 5 antigen-presenting cell; AQP4 5 aquaporin-4; Bc 5 B cell; Breg 5 regulatory B cell; DC 5 dendritic cell;
EAE 5 experimental autoimmune encephalomyelitis; GVHD 5 graft-vs-host disease; HLA 5 human leukocyte antigen; IL-10 5 interleukin 10; IVIg 5 IV
immunoglobulin; MS5multiple sclerosis; NMO/SD5 neuromyelitis optica/spectrum disease; NOD5 nonobese diabetes; T1D5 type 1 diabetes; Tc5 T cell;
TNF-a 5 tumor necrosis factor a; Treg 5 regulatory T cell.
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Likewise, TGFb-producing B cells have been generated
in vitro, and their adoptive transfer has suppressed
experimental T1D by inducing apoptosis of effector T
cells.e12,e13 These and related approaches could be
applied to NMO/SD.
Oral tolerization in NMO/SD. The gut-associated
lymphoid tissue is the largest immune organ and
naturally induces tolerance to ingested proteins.
Thus, oral tolerance represents a nontoxic and
physiologic mechanism by which to induce
tolerance in an antigen-specific manner.e14 While
oral tolerization has yet to be successfully translated
to human autoimmune diseases, it is effective in
human allergy.e15,e16 In those cases, patients are
desensitized to an offending allergen(s) by step-
wise exposure to that allergen. Emerging
evidence supports the potential for oral
tolerization in preventing or treating NMO/SD.
For example, NMO–immunoglobulin G (IgG)
is predominantly IgG1 and requires T cell
endorsement. Thus, antibody production in
NMO/SD is largely dependent on antigen-
restricted T cells. Furthermore, specific T cell
reactivity to AQP4 has been described,e17–e24
including identification of T cell epitopes.e25,e26
For example, Varrin-Doye et al.e17 identified an
immunodominant sequence of AQP4 (p61-80)
that is recognized by CD41 T cells from patients
with NMO. Furthermore, these cells exhibit a Th17
phenotype, consistent with the proinflammatory
immune profile observed in human NMO/SD,
including complement fixation and neutrophil
involvement.
Oral tolerization mitigates T cell–mediated disease
in animal models of EAE and nonobese diabetes.e14
Yet, it remains unknown whether orally administered
autoantigens can tolerize T cells and attenuate an
antibody-mediated neurologic disease. This question
appears to have been answered in principle using a rat
model of myasthenia gravis, where orally adminis-
tered acetylcholine receptor (AChR) peptide attenu-
ated the disease.e27 In concept, oral tolerization
in NMO/SD might be accomplished by feeding
AQP4 or its peptides, followed by immunization with
AQP4 with an appropriate adjuvant. This would be
followed by assaying cell proliferation and antibody
production to assess AQP4 tolerogenic responses.
Tolerization might be optimal at either low or high
dosages of antigen, although the mechanisms
involved may differ. For example, at lower dosages,
Tregs would be expected to have a prominent role,
whereas higher dosages may provoke anergy or cell
deletion. Animal studies could provide important
information regarding optimal dosing in initial
human NMO/SD. Varrin-Doyer et al.e17 suggest that
administration of either AQP4 protein or its immu-
nodominant peptide(s) may reduce relapse frequency
and/or severity in animal models of NMO/SD.
Oral modalities designed to tolerize autoreactive T
cells for therapy in human autoimmune disease are
being evaluated.e28 For example, initial results suggest
that insulin administered orally may delay T1D,
presumably by restoring immune tolerance to
insulin-reactive T cells.e29 For human NMO/SD, T
cell reactivity and AQP4 antibody levels would be
monitored pre- and postimmunization. This modal-
ity should be well tolerated. Theoretically, oral
administration of anti-CD3 monoclonal antibody
could induce Tregs to retolerize in NMO/SD. Results
using similar strategies have been encouraging in
EAE, diabetes mellitus, and lupus (reviewed in refer-
ence e28). Other modes of antigen administration
have also been explored with promising results. For
example, intranasal dosing of myelin basic protein
mitigates EAE in rats by activating IL-41/TGFb1
regulatory cells.e30 Similarly, intranasal administration
of purified AChR suppressed AChR-directed anti-
body production and disease manifestations in an
experimental rat model of myasthenia gravis.e31 Sim-
ilarly, other studies have used nasal dosing in autoim-
mune myocarditis and like conditions.
These approaches would in concept treat NMO/
SD regardless of the identities of the pathogenic auto-
antigen(s) involved. However, the nonspecific expan-
sion of Tregs could result in untoward consequences,
including infection or malignancy. Therefore, while
promising in principle, therapeutic efficacy of oral tol-
erization in NMO/SD and other human autoim-
mune diseases has yet to be proven, and faces
challenges.
OTHER STRATEGIES FOR IMMUNE TOLERIZATION/
IMMUNE DEVIATION Adoptive transfer immunotherapy.
Immune modulatory functions of Tregs are conferred
by expression of one or more cell-associated
determinants including CTLA-4, inducible T cell
costimulator (CD278), or lymphocyte activation
gene 3, as well as secreted factors such as TGFb
and IL-10.e32 Similarly, Bregs can modulate
immune responses through the elaboration of IL-
10 and TGFb.e33 AQP4-restricted Tregs and Bregs
could be adoptively transferred into a human
leukocyte antigen–matched recipient, where anti-
ergotypic lymphocytes could modulate pathogenic
effector cells. Safe and effective use of autologous
Treg immunotherapy has been demonstrated in
human GVHD,e34,e35 yet attempts at adoptive
transfer of Tregs in experimental models of
collagen-induced arthritis or lupuse36,e37 have
been only modestly successful. Challenges exist
in the use of adoptive transfer modalities. For
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example, minority Treg populations can lose Foxp3
expression and become pathogenic, IFN-g1 and
IL-171 phenotypes (i.e., T cell transdifferentiated
“ex-Foxp3” cells).e38,e39 Epigenetic modifications or
chromatin remodeling are other potential issues in
transferred or engrafted regulatory lymphocytes.e32,e40
Thus, durability and tissue-specific targeting of
regulatory lymphocytes are key areas that remain to
be optimized for immunotherapy of NMO/SD and
other autoimmune diseases.
Anti-idiotypic networks. Anti-AQP4 and antibodies
directed at alternate antigens have been implicated
in most patients with NMO/SD. Less well
understood is the potential role for protective or
anti-idiotypic antibodies in this disease. Anti-
idiotypic antibodies are known to modulate T1D,e41
myasthenia gravis,e42 and neonatal lupus syndrome.e43
Such antibodies target antigen-binding (Fab) domains
of pathogenic antibodies, interfering in their
pathogenic interactions with cognate targets. This
mechanistic principle is a likely basis for efficacy of
IVIg therapy in NMO/SD.e44,e45 In T1D, a decline in
anti-idiotypic antibodies targeting nonpathogenic,
GAD65 autoantibodies precedes disease.e46 While
this may be a valid surrogate biomarker, it suggests
that protective humoral responses may fend off the
onset or progression of certain autoimmune diseases.
Beyond passive administration of IVIg, anti-idiotypic
antibodies may mediate T cell tolerization strategies
targeting lupuse47 and MS.e48 Likewise, deviating B
cell response from proinflammatory IgG1 to
noninflammatory IgG4 isotype illustrates a potential
strategy for antibody response in NMO/SD to be
beneficially shifted. It is also noteworthy that
presence of anti-idiotypic antibodies can obscure
autoantibodies in certain diseases.e49 For example,
anti-idiotypic antibodies might limit NMO/SD
severity or render assays seronegative for NMO-IgG.
Anti-idiotypic antibody therapy may be feasible and is
worthy of exploration in NMO/SD.
Target-competitive antibody in tolerization. Engineering
of beneficial antibodies has also been pursued in
NMO/SD. A prominent example is aquaporumab,
a recombinant monoclonal antibody possessing high
affinity for AQP4 but lacking complement activation
or antibody-dependent cell cytotoxicity.e50 Currently
in preclinical development, aquaporumab aims
to passively tolerize patients by competing with
endogenous anti-AQP4, thereby sparing the pathogenic
targeting of astrocytes or other CNS targets.
TOLERIZATION CLINICAL DEVELOPMENT
ROADMAP Pilot studies evaluating the efficacy
of candidate therapies in NMO/SD have yielded
ambiguous results. These studies have proven
incomplete in informing phase III trial design.
This is especially true in pilot studies lacking con-
trol arms, where accurate measures of effect mag-
nitude and relative safety are compromised.
These estimates are critical in the initial assess-
ment of benefit–risk. Chief barriers to identifying
effective and safe antigen-specific treatments include
precisely defined target epitopes, optimal dosing
regimens, and identification of the most appropriate
subject cohorts. A comprehensive strategy for
addressing these challenges will be essential for
obtaining robust clinical trial outcomes (figure).
The feasibility of tolerization therapy in NMO/
SD is predicated on AQP4 or other pathogenic auto-
antigen(s) having a central role in disease process.
One challenge to success is the heterogeneity of the
disease. One strategy that may afford a best chance
for success would involve a therapeutic target(s) that
is common to a majority of NMO/SD cases. In indi-
viduals whose disease involves alternate autoantigens
or mechanisms, responses to tolerization directed at
AQP4 may diverge, potentially jeopardizing study
outcomes. Thus, each proposed tolerizing strategy
should include a systematic evaluation of all variables
that might confound study interpretation. These
measures include subject demographics, heterogeneity
in disease phenotype, and treatment history before
enrollment.
Figure Developmental pathway for tolerization therapies addressing
neuromyelitis optica/spectrum disorder
In this illustration, key developmental milestones are sequenced from laboratory discovery
(top) to clinical use (bottom). Approximate time (years) typically required to achieve each
developmental milestone is shown in the chevron symbols to the left of respective mile-
stones. Developmental goals (left column) and stages (right column) are also listed in relation
to respective developmental milestones. CMC 5 chemistry/manufacturing/control; IND 5
investigational new drug application; MoA 5 mechanism of action; NDA 5 new drug
application.
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Patient diversity in NMO/SD remains incom-
pletely understood, particularly in those cases in
which NMO-IgG cannot be detected. This point il-
lustrates how the stringency of trial inclusion and
exclusion criteria must be counterbalanced by the
ultimate importance of assessing as broad a subject
population as is possible. Assessment of a diverse
patient population is essential to the identification
of all patients who might benefit from therapy. Thus,
early recognition of likely regulatory requirements
and intended scope of clinical use is critical to the
design of trial programs.
Disease stage may also determine efficacy of toleriza-
tion therapy. Early disease might prove particularly ame-
nable to tolerance enhancement aimed at minimizing
epitope spreading. NMO/SD cases that progress might
exhibit aberrations of immunity differing from those
in early, self-limited disease. In designing clinical trials,
patients with advanced disease may have accumulated
significant disability. This fact can complicate the dem-
onstration of efficacy, as additional dysfunction could
escape clinical detection. Establishing a suitable range
of disease duration or severity in the inclusion criteria
will be required in assessing treatment efficacy.
Previous treatment exposure is likely to influence
reestablishment of immune tolerance. In this regard,
stratification of study participants with respect to
prior drug treatment, temporal remoteness of earlier
therapies, and other therapeutic history must be con-
sidered carefully. Because tolerization therapy requir-
ing autologous reagents highlights factors unique to
each patient, full assessment of immune function in
each subject will be necessary before study enrollment.
Attempts at gaining registration for therapies
aiming to restore immune tolerance are likely to
encounter multiple hurdles, some of which are
unique. Several of the tolerance-restoring strategies
mentioned have safely navigated phase I clinical tri-
als in other autoimmune conditions. Nonetheless,
prospective and rigorous evaluation of safety in
larger numbers of patients with NMO/SD will be
necessary for any tolerization strategy going forward.
For example, the potential for regulatory cells to
revert to inflammatory effector phenotypes is a con-
cern. Likewise, strategies that attenuate regulatory
mechanisms in concept might promote disease exacer-
bation if excessive IL-10 or other factors are elabo-
rated. Because of their potential to significantly alter
normal immune function, tolerization therapies will
likely engender high-level expectations for safety.
Access to an adequate and appropriate subject
cohort is essential to establishing the safety, efficacy,
and dose-optimization of a candidate agent. Devel-
opment and validation of new trial outcome meas-
ures and diagnostic biomarkers will facilitate trial
designs that enhance the likelihood to yield
unambiguous results. Optimizing early-phase study
design promotes the success of subsequent phase
III trials. This experience may be particularly true
for strategies attempting immune retolerization,
whereby the details a priori of optimal dosing are
essentially unknown. Sample size determinations
will depend on a number of factors, including the
following: (1) stringent and objective definitions of
relapse and severity; (2) estimates of relapse fre-
quency; (3) reduction of relapse frequency by an
experimental treatment vs a comparator; (4) time
to onset of efficacy; (5) error assumptions around
the point estimates for control; and (6) choice of
a-power level required to reject the null hypothesis.
The choice of appropriate comparator(s) is key to
designing any clinical trial. Inclusion of arms receiving
pure placebo, unproven currently used therapies, or add-
on combinations in NMO/SD has recently been revie-
wed.e51 Use of an unproven yet widely used drug(s) as
a comparator imposes substantial challenges to demon-
strating superiority or noninferiority, as the comparator
effect would remain undetermined.
Designing robust NMO/SD efficacy and safety trials
to support drug registration will require substantial input
from the relevant regulatory agencies. Thus, their early
guidance on every aspect of the trial design should be
sought. Their input regarding safety, dosing, and study
endpoints is essential. The data generated from each trial
will ultimately inform product labeling and patient
access, and will likely shape clinical practice. It should
also be noted that 2 adequate and well-controlled confir-
matory trials are typically required as evidentiary for
approval. In rare circumstances, a single pivotal trial gen-
erating unambiguous results may suffice, especially in the
orphan disease space.e52 As safety will be a major driver of
benefit–risk assessment, early endorsement of the safety
monitoring details and plan should be obtained from
regulatory authorities.
In summary, meeting the scientific, operational,
ethical, and regulatory hurdles for developing novel
therapeutics in rare neuroimmunologic diseases such
as NMO/SD is challenging. Nonetheless, strategies
aimed at restoring immune tolerance may offer
favorable long-term safety compared to chronic
immunosuppression. No therapies currently used
in NMO/SD have been proven effective or safe in
controlled, prospective clinical trials. This fact highlights
the unmet need and justifies the continued efforts of re-
searchers and clinicians in close collaboration with indus-
try and regulatory partners to facilitate development of
tolerizing therapies for NMO/SD.
CONCLUDING REMARKS The goal of immune tol-
erization is to reset the immune system and restore
central and peripheral tolerance and in so doing
overcome manifestations of autoimmune disease.
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This primary goal faces difficult challenges, includ-
ing disease heterogeneity, the dynamics of adaptive
immunity, and inflammatory responses over the
course of disease. The strategies discussed in these
articles may prove successful in reducing immune
reactivity targeting pathogenic autoantigens in
NMO/SD. To do so, tolerization therapeutics must
delete autoreactive effector cells or attenuate their
functions, and prevent their re-emergence. In
theory, efficacy may be achieved by modulating
inflammatory or enhancing regulatory responses.
The value of these approaches will ultimately be
determined by their efficacy in reducing or
eliminating disease morbidity and mortality. In
practice, the combination of traditional and
retolerization strategies may be a first step forward,
where conditioning of the immune system through
one approach affords a permissive groundwork for
retolerization. In this respect, a development process in
which adaptive trial designs may afford the most
efficient advances may be ideal. Obviously, identifying
durable curative and preventive measures remains the
ultimate goal for these strategies. Despite its challenges,
restoring immune tolerance remains a meritorious and
promising goal in NMO/SD.
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